Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy—let’s define who benefits the most

Eric Santoni-Rugiu; Jens Benn Sørensen; Edyta Maria Urbanska

doi:10.21037/tlcr-24-961

Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy—let’s define who benefits the most

Eric Santoni-Rugiu^*, Jens Benn Sørensen, Edyta Maria Urbanska

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

2 Downloads (Pure)

Originalsprog	Engelsk
Tidsskrift	Translational Lung Cancer Research
Vol/bind	14
Udgave nummer	2
Sider (fra-til)	310-313
Antal sider	4
ISSN	2218-6751
DOI	https://doi.org/10.21037/tlcr-24-961
Status	Udgivet - 2025

Adgang til dokumentet

10.21037/tlcr-24-961Licens: CC BY-NC-ND

FulltextForlagets udgivne version, 135 KBLicens: CC BY-NC-ND

Citationsformater

Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy—let’s define who benefits the most. / Santoni-Rugiu, Eric ; Sørensen, Jens Benn; Urbanska, Edyta Maria.
I: Translational Lung Cancer Research, Bind 14, Nr. 2, 2025, s. 310-313.

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

@article{d679788fb6704a7baa6ef250967738f4,

title = "Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy—let{\textquoteright}s define who benefits the most",

keywords = "Adjuvant alectinib, anaplastic lymphoma kinaserearranged NSCLC (ALK-rearranged NSCLC), resected early-stage non-small cell lung cancer (resected early-stage NSCLC)",

author = "Eric Santoni-Rugiu and S{\o}rensen, {Jens Benn} and Urbanska, {Edyta Maria}",

year = "2025",

doi = "10.21037/tlcr-24-961",

language = "English",

volume = "14",

pages = "310--313",

journal = "Translational Lung Cancer Research",

issn = "2218-6751",

publisher = "Society for Translational Medicine (STM)",

number = "2",

}

TY - JOUR

T1 - Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy—let’s define who benefits the most

AU - Santoni-Rugiu, Eric

AU - Sørensen, Jens Benn

AU - Urbanska, Edyta Maria

PY - 2025

Y1 - 2025

KW - Adjuvant alectinib

KW - anaplastic lymphoma kinaserearranged NSCLC (ALK-rearranged NSCLC)

KW - resected early-stage non-small cell lung cancer (resected early-stage NSCLC)

U2 - 10.21037/tlcr-24-961

DO - 10.21037/tlcr-24-961

M3 - Comment/debate

AN - SCOPUS:85219549043

SN - 2218-6751

VL - 14

SP - 310

EP - 313

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

IS - 2

ER -